[{"id":"estrogen-receptor","kind":"target","name":"Estrogen receptor (ERα)","route":"/targets/estrogen-receptor/","commit":"91a4bba51c","date":"2026-09-10","author":"Jude Gomila","message":"Fourteen orphan products now linked from their targets and cancers (ALK, EGFR, ROS1, ER, FOLR1 inhibitors and tracers; myeloma, prostate, gl","file":"src/data/targets.ts","type":"changed","fields":[{"field":"drugs","after":"[\"fluoroestradiol-f18\"]"}]},{"id":"estrogen-receptor","kind":"target","name":"Estrogen receptor (ERα)","route":"/targets/estrogen-receptor/","commit":"cebb34a709","date":"2026-09-08","author":"Jude Gomila","message":"Guideline mapping on every standard-of-care row; sourced biomarker prevalence for 59 targets; GuidelineChip, PrevalenceTable, CancerPrevalen","file":"src/data/targets.ts","type":"changed","fields":[{"field":"prevalence","after":"[\n      { cancerId: \"breast-hr-positive\", pct: 100, measure: \"ER+ (>=1% IHC), defining\", source: \"https://en.wikipedia.org/wiki/Estrogen_receptor_alpha\", note: \"~70% of all breast cancers; ESR1 mutation ~30% after AI\"..."}]}]